In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic ...
In an analysis from the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Lu et al found that the presence of NOTCH1 mutation was associated with improved overall survival in patients receiving second-line tislelizumab vs investigator’s choice of chemotherapy for advanced...
In the French phase II PANACHE01-PRODIGE48 trial, researchers found that neoadjuvant chemotherapy with mFOLFIRINOX (modified leucovorin, fluorouracil, irinotecan, and oxaliplatin) was feasible and active in patients with resectable pancreatic adenocarcinoma. Schwarz et al published these findings...
In a UK phase III trial (UKALL 2011) reported in the Journal of Clinical Oncology, Kirkwood et al found that a shorter duration of induction dexamethasone did not reduce steroid-related toxicity and that high-dose methotrexate (HDM) did not reduce central nervous system (CNS) relapse among patients ...
In the API-CAT trial—results of which were reported in The New England Journal of Medicine—Mahé et al found that use of reduced-dose apixaban was noninferior to full-dose apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer. Study Details In the double-blind...
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al reported activity with the antibody-drug conjugate (ADC) FOR46 in patients with metastatic castration-resistant prostate cancer. As stated by the investigators, “FOR46, a fully human antibody conjugated to monomethyl...
In a Spanish study (COLONPREV) reported in The Lancet, Castells et al found that invitation to fecal immunochemical test (FIT) vs colonoscopy screening for colorectal cancer was associated with noninferiority in colorectal cancer mortality. Study Details In the multicenter study, eligible...
In a Japanese trial (JCOG0905) reported in the Journal of Clinical Oncology, Hiraga et al found no disease-free survival benefit with the addition of a higher dose of ifosfamide to methotrexate, doxorubicin, and cisplatin (MAP) in patients with newly diagnosed high-grade osteosarcoma with poor...
In an analysis from the phase III TALAPRO-2 trial reported in The Lancet Oncology, Matsubara et al found that first-line talazoparib plus enzalutamide was associated with prolonged time to definitive deterioration in global health status/quality of life (GHS/QOL) vs placebo plus enzalutamide in...
In an analysis from the phase III MIRASOL trial reported in The Lancet Oncology, Van Gorp et al found no significant difference in quality of life between patients receiving mirvetuximab soravtansine vs chemotherapy for folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer. In...
In a U.S. population–based cohort study reported in JAMA Network Open, Bari et al identified patterns of immune checkpoint inhibitor (ICI) use and survival outcomes among patients with metastatic colorectal cancer seen in routine clinical practice. The investigators stated: “…ICIs have been...
In a U.K. trial (TRANSLATE) reported in The Lancet Oncology, Bryant et al found that local anesthetic transperineal (LATP) prostate biopsy detected more Gleason Grade Group (GGG) ≥ 2 prostate cancer compared with transrectal ultrasound (TRUS)-guided biopsy in previously biopsy-naive individuals who ...
In a single-center study reported in JAMA Network Open, Alsavaf et al attempted to identify patient characteristics and treatment outcomes of nasopharyngeal carcinoma in the United States, a nonendemic region of the disease. Study Details The retrospective cohort study included patients with...
In a study reported as a research letter in JAMA Oncology, Caturegli et al attempted to identify smoking status of patients diagnosed with cancer in the United States in 2023. Study Details In the cross-sectional study, the smoking status of patients diagnosed with cancer in 2023 was collected by...
In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelines vs the prior guidelines. In 2021, the USPSTF updated lung cancer screening guidelines by...
In a French phase II trial (iNDUCT-GETUG V08) reported in the Journal of Clinical Oncology, Houédé et al found evidence of activity of neoadjuvant durvalumab plus chemotherapy in patients with high-risk, upper tract urothelial carcinoma. Study Details In this multicenter open-label trial, 45...
In a study reported in JAMA Oncology, Yeh et al found evidence of accelerated aging in survivors of childhood cancers through the observed increased risk and early onset of age-related diseases. Study Details The study focused on data from the Childhood Cancer Survivor Study and national databases...
In a UK prospective longitudinal cohort study (SUMMIT) reported in The Lancet Oncology, Bhamani et al found that large-scale, low-dose computed tomography (CT) screening for lung cancer is effective and “can be delivered efficiently” in a diverse high-risk population. As stated by the...
In an Israeli retrospective cohort study reported as a research letter in JAMA Network Open, Armon et al found that presymptomatic awareness of BRCA1/BRCA2 pathogenic variant carrier status was associated with better outcomes in several measures in women with ovarian cancer. Study Details The...
In a Dutch noninferiority phase III trial (SANO) reported in The Lancet Oncology, van der Wilk et al found that active surveillance was noninferior to standard surgery in terms of 2-year overall survival among patients with esophageal cancer who had a clinical complete response after neoadjuvant...
In a single-center phase II trial (DEPEND) reported in JAMA Oncology, Rosenberg et al found that the combination of neoadjuvant nivolumab and chemotherapy followed by response-stratified chemoradiation (CRT) was active in human papillomavirus (HPV)-negative stage IVa/b head and neck squamous cell...
In a health-related quality-of-life (QOL) analysis reported in The Lancet Oncology, Powles et al found that belzutifan had better QOL on patient-reported outcomes vs everolimus in patients with advanced renal cell carcinoma in the phase III LITESPARK-005 trial. Study Details Belzutifan is approved...
In a study reported in JAMA Network Open, Shrestha et al found that receipt of recommended care and treatment outcomes were associated with geographic access to care in U.S. patients with early-stage non–small cell lung cancer (NSCLC). Study Details The study involved data from the Surveillance,...
In a French study reported in the Journal of Clinical Oncology, Dumas et al found that improved endocrine therapy (ET) persistence among young patients with hormone receptor (HR)-positive early breast cancer would likely lead to improved disease-free survival. Study Details The study used data from ...
In a Scottish study (TEMPO) reported in The Lancet, Robb et al found that a behavioral intervention adding a deadline for fecal immunochemical testing (FIT) return in the invitation letter to FIT colorectal cancer screening resulted in superior uptake of testing. Study Details In the trial, 40,000...
In a study reported in JAMA Oncology, Agusti et al found that the addition of chemotherapy to adjuvant radiotherapy was not associated with improved overall survival in patients with intermediate-risk cervical cancer. Study Details The study involved National Cancer Database data on patients with a ...
In a systematic review and meta-analysis reported in JAMA Network Open, Yajima et al found that both pembrolizumab plus enfortumab vedotin-ejfv and enfortumab vedotin alone were active in the first-line setting and later lines of therapy, respectively, in metastatic urothelial carcinoma. Study...
In an individual patient data meta-analysis reported in The Lancet Oncology, Kishan et al found that isodose and dose-escalated moderately hypofractionated radiotherapy exhibited similar efficacy vs conventionally fractionated radiotherapy in patients with localized prostate cancer. They also...
In a phase Ia/Ib study (Beamion LUNG-1) reported in the Journal of Clinical Oncology, Heymach et al evaluated the safety profile and activity of zongertinib in patients with HER2-altered solid tumors. Zongertinib is a novel HER2-selective tyrosine kinase inhibitor (TKI) that spares EGFR, thereby...
As reported in the Journal of Clinical Oncology by Adi Diab, MD, and colleagues, the phase III ILLUMINATE trial showed adding the Toll-like receptor-9 agonist tilsotolimod to ipilimumab in patients with advanced refractory melanoma produced no benefit. Study Details Four hundred and eighty-one...
In an interim analysis of a Chinese phase III trial (HARMONi) reported in The Lancet, Xiong et al found that ivonescimab—a bispecific antibody against PD-1 and VEGF—significantly improved progression-free survival vs pembrolizumab in the first-line setting for patients with advanced PD-L1–positive...
In a German single-center trial (POLAR) reported in JAMA Oncology, Michel et al found that hand cooling and hand compression were associated with a reduced risk of taxane-induced neuropathy in women with primary breast cancer. Study Details In the trial, 101 patients enrolled at the National Center ...
In the phase II Neo-N trial reported in The Lancet Oncology, Zdenkowski et al found no apparent advantage of lead-in nivolumab in neoadjuvant therapy comprised of nivolumab/carboplatin/paclitaxel for patients with early triple-negative breast cancer. Study Details In the investigator-initiated,...
As reported in the Journal of Clinical Oncology by Gianni Bisogno, MD, PhD, and colleagues, long-term follow-up of the European Paediatric Soft Tissue Sarcoma Study Group RMS2005 trial showed significant survival advantages with the use of maintenance chemotherapy in pediatric patients with...
In a study reported as a research letter in JAMA Network Open, Amboree et al found that women with cervical cancer living in rural U.S. counties had poorer outcomes than those living in urban counties. Study Details The trial used data from the National Program of Cancer Registries and...
In a Japanese phase II trial (MARBLE) reported in The Lancet Oncology, Shukuya et al found that atezolizumab plus carboplatin/paclitaxel showed promising results in patients with recurrent or metastatic thymic carcinoma. Study Details In the multicenter trial, 48 patients enrolled between June 2022 ...
In a phase II trial reported in Journal of Clinical Oncology, Weiss et al found that the combination of pembrolizumab and bevacizumab was active in patients with previously untreated melanoma brain metastases. Study Details In the trial, 37 patients, enrolled at Yale Cancer Center and Moffitt...
In a study reported in the Journal of Clinical Oncology, Veenstra et al found that pathogenic variants (PVs) in ATM, CHEK2, or PALB2 were not associated with significant differences in mortality from breast, colorectal, or pancreatic cancer compared with the absence of such PVs. Study Details The...
In an analysis reported as a letter to the editor in The New England Journal of Medicine, Rousseau et al found a relationship between the duration of neoadjuvant immunotherapy and the likelihood of pathologic complete response in patients with localized mismatch repair–deficient (MMRd) colorectal...
In a retrospective cohort study reported in JAMA Network Open, Podany et al identified differences in circulating tumor DNA (ctDNA) profiles, targeted therapy use, and survival outcomes in Black vs White patients with metastatic breast cancer. Study Details The U.S. multicenter study involved 1,327 ...
As reported in the Journal of Clinical Oncology by Petrylak et al, the phase III KEYNOTE-921 trial showed no benefit in outcomes with the addition of pembrolizumab to docetaxel in patients with previously treated metastatic castration-resistant prostate cancer. Study Details In the global...
In an Italian single-center phase II trial (RADIOSA) reported in The Lancet Oncology, Marvaso et al found that the addition of androgen-deprivation therapy (ADT) to stereotactic body radiotherapy (SBRT) improved progression-free survival in patients with hormone-sensitive oligorecurrent prostate...
In a study reported in The Lancet Oncology, Dee et al identified cancer incidence and mortality rates for 2022 in the countries of southeast Asia. Study Details The study involved data from the GLOBOCAN 2022 database developed by the International Agency for Research on Cancer for the 11 countries...
In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Berko et al identified the spectrum and clinical significance of clonal and subclonal pathogenic alterations in high-risk neuroblastoma. Study Details The study involved use of a focused high-risk neuroblastoma ...
In a retrospective study reported in JAMA Network Open, Lim et al found that complete response to immunotherapy as first-line treatment of advanced hepatocellular carcinoma was associated with good outcomes. Study Details The study involved analysis of 228 patients who received atezolizumab and...
In a single-center phase I/II trial reported in JAMA Oncology, Floudas et al found that the combination of the human papillomavirus (HPV) type 16 therapeutic vaccine PDS0101, the tumor-targeting interleukin-12 antibody-drug conjugate PDS01ADC, and the bifunctional PD-L1/TGF-β inhibitor bintrafusp...
In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...
In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...
In a study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, and colleagues identified clinical characteristics of breast cancer in young women carrying germline pathogenic variants in BRCA1 vs BRCA2 and examined the effect of prediagnostic BRCA testing on outcomes. Study...
In a retrospective study reported in the Journal of Clinical Oncology, Hansen et al found that standard-of-care ciltacabtagene autoleucel was associated with better efficacy outcomes and increased risk of some toxicities vs standard-of-care idecabtagene vicleucel in patients with relapsed or...